Web Date: May 9, 2017
Researcher sues Harvard for drug royalties
A former Harvard University postdoctoral researcher has sued the university for his share of $20 million that Merck & Co. paid Harvard in 2016 to license preclinical compounds to treat leukemia. At the time, the license fee was called the largest ever for a technology developed at Harvard.
The researcher, Alexander Arefolov, worked in the lab of Harvard chemist Matthew Shair between 2011 and 2015. He claims that . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society